Genfit S.A. (GNFT)
| Market Cap | 206.72M |
| Revenue (ttm) | 46.02M |
| Net Income (ttm) | -73.20M |
| Shares Out | 36.18M |
| EPS (ttm) | -1.98 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $5.40 |
| Previous Close | $5.72 |
| Change ($) | -0.32 |
| Change (%) | -5.59% |
| Day's Open | 5.40 |
| Day's Range | 5.27 - 5.51 |
| Day's Volume | 17,174 |
| 52-Week Range | 3.63 - 22.00 |
LOS ANGELES--(BUSINESS WIRE)---- $GNFT #GNFT--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Genfit SA
Lille, France; Cambridge, MA; January 13, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and live...
Lille, France; Cambridge, MA; January 11, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and live...
Lille, France; Cambridge, MA; January 8, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver...
Lille, France; Cambridge, MA; January 6, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver...
SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $GNFT #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Genfit SA American Depository Shares (NASDAQ: GNFT) ...
LOS ANGELES--(BUSINESS WIRE)---- $GNFT #classaction--The Law Offices of Frank R. Cruz Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)---- $GNFT #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)---- $GNFT #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors
Lille (France), Cambridge (Massachusetts, United States), December 7, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of pati...
Lille (France), Cambridge (Massachusetts, United States), November 30, 2020 – GENFIT (Nasdaq and Euronext: GNFT) a late-stage biopharmaceutical company dedicated to improving the lives of pati...
Lille (France), Cambridge (Massachusetts, United States), November 23, 2020 – GENFIT (Nasdaq and Euronext: GNFT) a late-stage biopharmaceutical company dedicated to improving the lives of pati...
Lille (France), Cambridge (Massachusetts, United States), November 16, 2020 – GENFIT (Nasdaq and Euronext: GNFT a late-stage biopharmaceutical company dedicated to improving the lives of patie...
GENFIT SA (GNFT) CEO Pascal Prigent on Q2 2020 Results - Earnings Call Transcript
Genfit SA (NASDAQ: GNFT) shot up on Monday after the company announced an agreement with Lab Corporation of America Holdings (NYSE: LH).
Lille, France; Cambridge, M.A.; September 24, 2020 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and ...
Lille, France; Cambridge, M.A.; September 22, 2020 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and ...
Lille, France; Cambridge, M.A.; August 26, 2020 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liv...
Lille (France), Cambridge (Massachusetts, United States), August 05, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patie...
Genfit (GNFT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Genfit’s (NASDAQ:GNFT) loss may be a gain for other companies developing a treatment for one of the most rapidly growing health problems around the world, particularly Intercept Pharmaceutical...
Non-alcoholic steatohepatitis biotechs are increasingly finding it difficult to make headway, and the lack of any approved therapy despite a slew of research is a testament to the challenge.
One of the company's pipeline candidates flopped in a late-stage clinical trial.
Genfit stock lost half its value late Monday after the biotech company's promising hepatitis treatment failed in a Phase 3 test. The results are a boon for rival Intercept Pharmaceuticals.
Genfit (GNFT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
The U.S. Food and Drug Administration is scheduled to make decisions on five therapies in the second quarter, and the one that could make the biggest impact on the company and its shares belon...
Genfit: Near-Term Upside Of 650% As Read-Out Of The Year Approaches
As of late, it has definitely been a great time to be an investor in Genfit.
A French biopharmaceutical company hopes to become the first to gain approval of a drug to treat a widespread liver disease.
Both companies aim to grab a piece of the multi-billion dollar market for treating patients with the liver disease NASH. So, which one should you buy?
Genfit (NASDAQ: GNFT) on Monday afternoon announced a partnership with Terns Pharmaceuticals to develop and commercialize Elafibranor in Greater China.
Genfit expects to report interim results from its phase 3 NASH study, which is expected to be read out by the end of 2019.
Genfit received Breakthrough Therapy Designation from the FDA for its Elafibranor to treat patients with primary biliary cholangitis.
They're risky, but these up-and-coming biotechs could be tremendous winners for investors willing to take on those risks.
About GNFT
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-indu... [Read more...]
| Industry Biotechnology | IPO Date Mar 27, 2019 |
| CEO Pascal Prigent | Employees 203 |
| Stock Exchange NASDAQ | Ticker Symbol GNFT |
Financial Performance
In 2019, Genfit's revenue was 40.96 million, an increase of 446.58% compared to the previous year's 7.49 million. Losses were -65.14 million, -18.08% less than in 2018.